NCT00418509已完成1 期
A Randomized, Single Dose, 3-Period Crossover Study to Evaluate the Dosage Form Proportionality, Dose Proportionality and Pharmacokinetics of Mometasone Furoate and Formoterol Fumarate From Three Combination MDI Formulations
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Dosage form and dose proportionality of mometasone and formoterol from combination metered dose inhalers (MDI).
研究概览
简要总结
This study will compare the performance of three combination metered dose inhalation devices and the variability of mometasone and formoterol doses delivered to the lungs in a healthy volunteer population
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, male or female subjects age 18 to 65 years of age (included)
- •In good health as confirmed by past medical history
- •Female subjects must be either surgically sterilized at least 6 months prior to study participation or post-menopausal (no regular menstrual bleeding for at least 2 years)
- •Body mass index (BMI) within the range of 18.5 to 32 kg/m2 and weigh at least 50 kg
- •Able to communicate well with the investigator, to understand and comply with the requirements of the study
- •Understand and sign the written informed consent
排除标准
- •Smokers (use of tobacco products in the previous 1 year with a pack year history of no greater than 10 pack years).
- •Female subjects who are pregnant, or lactating
- •Treatment with any oral or intravenous corticosteroids within 1 month of the first study treatment.
- •Patients with a current respiratory tract infection or one within 1 month prior to screening.
- •Patients with a history of malignancy, myocardial infarction, untoward reactions to sympathomimetic amines or inhaled medicine.
- •Subjects with a current or history of a clinically significant cardiac arrhythmia.
- •Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.
- •Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.
- •Significant illness within the two weeks prior to dosing.
- •A past medical history of clinically significant ECG abnormalities.
- •History of fainting, known hypersensitivity to the study drug or drugs similar to the study drug. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study, immunocompromise, including a positive HIV (ELISA and Western blot) test result, positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result, drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening evaluations.
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Dosage form and dose proportionality of mometasone and formoterol from combination metered dose inhalers (MDI).
次要结局
- Plasma and urine concentrations mometasone and formoterol
- Extrapulmonary (systemic) effects and safety of mometasone and formoterol from combination MDI formulations.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated NebulizersAsthmaNCT02777125Le Bonheur Children's Hospital980
已完成
1 期
Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human InsulinHealthyNCT00511979Mannkind Corporation12
招募中
4 期
Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass ExposureCOPD BronchitisPollution Related Respiratory DisorderNCT06571942National Institute of Respiratory Diseases, Mexico128
Unknown
1 期
PK/PD Study of Intranasal Insulin in Type I DiabetesType 1 DiabetesNCT01201278Hompesch, Marcus, M.D.20
已完成
1 期
Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone PropionateHealthyNCT02232087Kindeva Drug Delivery52